CR8603A - Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos - Google Patents
Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitosInfo
- Publication number
- CR8603A CR8603A CR8603A CR8603A CR8603A CR 8603 A CR8603 A CR 8603A CR 8603 A CR8603 A CR 8603A CR 8603 A CR8603 A CR 8603A CR 8603 A CR8603 A CR 8603A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitor
- compound
- mastocyt
- triptase
- aminometil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica que comprende una cantidad farmaceuticamente eficaz del compuesto de formula I, y un vehiculo farmaceuticamente aceptable. Ademas, la presente invencion se refiere al uso de un compuesto de formula I como inhibidor de triptasa, que comprende introducir el compuesto en una composicion que comprende triptasa. Ademas la presente invencion se refiere al uso de un compuesto de formula I para tratar a un paciente que padece o propenso a padecer una afeccion fisiologica que necesita la mejora de un inhibidor de triptasa que comprende administrar al paciente una cantidad terapeuticamente eficaz del compuuesto de la reivindicacion I.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55692704P | 2004-03-26 | 2004-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR8603A true CR8603A (es) | 2007-06-08 |
Family
ID=34964263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR8603A CR8603A (es) | 2004-03-26 | 2006-09-07 | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070142435A1 (es) |
| EP (1) | EP1737848A1 (es) |
| JP (1) | JP2007530580A (es) |
| KR (1) | KR20060130682A (es) |
| CN (1) | CN1956978A (es) |
| AR (1) | AR048336A1 (es) |
| AU (1) | AU2005230934A1 (es) |
| BR (1) | BRPI0509245A (es) |
| CA (1) | CA2560649A1 (es) |
| CR (1) | CR8603A (es) |
| DO (1) | DOP2005000039A (es) |
| EC (1) | ECSP066878A (es) |
| IL (1) | IL178031A0 (es) |
| MA (1) | MA28547B1 (es) |
| MX (1) | MXPA06010610A (es) |
| NO (1) | NO20064811L (es) |
| PA (1) | PA8627601A1 (es) |
| PE (1) | PE20060084A1 (es) |
| RU (1) | RU2330034C1 (es) |
| TN (1) | TNSN06278A1 (es) |
| TW (1) | TW200602035A (es) |
| UA (1) | UA83738C2 (es) |
| UY (1) | UY28821A1 (es) |
| WO (1) | WO2005097780A1 (es) |
| ZA (1) | ZA200607752B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20071148A1 (es) * | 2006-03-29 | 2007-12-10 | Sanofi Aventis | Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona |
| AR065616A1 (es) * | 2007-03-07 | 2009-06-17 | Sanofi Aventis | Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico |
| WO2008115912A1 (en) * | 2007-03-21 | 2008-09-25 | Sanofi-Aventis | Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid |
| WO2008121669A1 (en) * | 2007-03-29 | 2008-10-09 | Sanofi-Aventis | 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto |
| WO2008121666A1 (en) * | 2007-03-29 | 2008-10-09 | Sanofi-Aventis | Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone |
| JP2011504499A (ja) * | 2007-11-21 | 2011-02-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリプターゼ阻害剤として使用するためのスピロピペリジン |
| NZ587119A (en) * | 2008-01-24 | 2013-01-25 | Soligenix Inc | Use of beclomethasone dipropionate in the treatment of an interstitial lung disease |
| CN102149705B (zh) * | 2008-08-22 | 2013-08-07 | 赛诺菲-安万特 | 作为肥大细胞类胰蛋白酶抑制剂的[4-(5-氨基甲基-2-氟苯基)-哌啶-1-基]-[7-氟-1-(2-甲氧基乙基)-4-三氟甲氧基-1h-吲哚-3-基]-甲酮 |
| TW201034675A (en) | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
| FR2955324A1 (fr) * | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
| SG179201A1 (en) | 2009-09-24 | 2012-05-30 | Sanofi Aventis Us Llc | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof |
| JP2013515724A (ja) * | 2009-12-23 | 2013-05-09 | サノフイ | ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類 |
| WO2011078983A1 (en) * | 2009-12-23 | 2011-06-30 | Sanofi | Treatment for inflammatory bowel disease |
| EP2516419A1 (en) * | 2009-12-23 | 2012-10-31 | Sanofi | Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors |
| AU2011220909A1 (en) * | 2010-02-24 | 2012-09-13 | Sanofi | Treatment of dermatological allergic conditions |
| CN103842356B (zh) | 2011-10-07 | 2017-03-15 | 武田药品工业株式会社 | 用于治疗神经变性疾病的1‑芳基羰基‑4‑氧‑哌啶化合物 |
| RU2771485C2 (ru) * | 2017-02-10 | 2022-05-04 | Дженентек, Инк. | Антитела против триптазы, их композиции и применения |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0111206A (pt) * | 2000-05-22 | 2003-04-15 | Aventis Pharma Inc | Derivados de arilmetilamina para uso como inibidores de triptase |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
-
2005
- 2005-03-21 DO DO2005000039A patent/DOP2005000039A/es unknown
- 2005-03-22 PE PE2005000325A patent/PE20060084A1/es not_active Application Discontinuation
- 2005-03-23 AR ARP050101170A patent/AR048336A1/es not_active Application Discontinuation
- 2005-03-23 UY UY28821A patent/UY28821A1/es unknown
- 2005-03-24 EP EP05731154A patent/EP1737848A1/en not_active Withdrawn
- 2005-03-24 RU RU2006137717/04A patent/RU2330034C1/ru not_active IP Right Cessation
- 2005-03-24 CA CA002560649A patent/CA2560649A1/en not_active Abandoned
- 2005-03-24 JP JP2007505191A patent/JP2007530580A/ja not_active Abandoned
- 2005-03-24 AU AU2005230934A patent/AU2005230934A1/en not_active Abandoned
- 2005-03-24 MX MXPA06010610A patent/MXPA06010610A/es not_active Application Discontinuation
- 2005-03-24 UA UAA200611261A patent/UA83738C2/ru unknown
- 2005-03-24 KR KR1020067019886A patent/KR20060130682A/ko not_active Application Discontinuation
- 2005-03-24 BR BRPI0509245-0A patent/BRPI0509245A/pt not_active IP Right Cessation
- 2005-03-24 CN CNA2005800164250A patent/CN1956978A/zh active Pending
- 2005-03-24 WO PCT/US2005/009899 patent/WO2005097780A1/en active Application Filing
- 2005-03-25 TW TW094109209A patent/TW200602035A/zh unknown
- 2005-03-28 PA PA20058627601A patent/PA8627601A1/es unknown
-
2006
- 2006-09-07 CR CR8603A patent/CR8603A/es not_active Application Discontinuation
- 2006-09-12 IL IL178031A patent/IL178031A0/en unknown
- 2006-09-12 TN TNP2006000278A patent/TNSN06278A1/en unknown
- 2006-09-14 US US11/520,998 patent/US20070142435A1/en active Granted
- 2006-09-15 ZA ZA200607752A patent/ZA200607752B/en unknown
- 2006-09-22 EC EC2006006878A patent/ECSP066878A/es unknown
- 2006-10-20 MA MA29405A patent/MA28547B1/fr unknown
- 2006-10-23 NO NO20064811A patent/NO20064811L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN06278A1 (en) | 2007-12-03 |
| CA2560649A1 (en) | 2005-10-20 |
| ECSP066878A (es) | 2006-11-24 |
| JP2007530580A (ja) | 2007-11-01 |
| MA28547B1 (fr) | 2007-04-03 |
| AR048336A1 (es) | 2006-04-19 |
| PA8627601A1 (es) | 2006-01-23 |
| CN1956978A (zh) | 2007-05-02 |
| EP1737848A1 (en) | 2007-01-03 |
| NO20064811L (no) | 2006-10-23 |
| WO2005097780A1 (en) | 2005-10-20 |
| UA83738C2 (en) | 2008-08-11 |
| TW200602035A (en) | 2006-01-16 |
| RU2006137717A (ru) | 2008-05-10 |
| PE20060084A1 (es) | 2006-03-09 |
| DOP2005000039A (es) | 2005-10-31 |
| UY28821A1 (es) | 2005-10-31 |
| AU2005230934A1 (en) | 2005-10-20 |
| US20070142435A1 (en) | 2007-06-21 |
| IL178031A0 (en) | 2006-12-31 |
| ZA200607752B (en) | 2008-05-28 |
| MXPA06010610A (es) | 2006-12-15 |
| KR20060130682A (ko) | 2006-12-19 |
| RU2330034C1 (ru) | 2008-07-27 |
| BRPI0509245A (pt) | 2007-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8603A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| CR9348A (es) | Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer | |
| DE60332629D1 (de) | Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
| CO6341624A2 (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
| WO2006108682A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents | |
| MY156278A (en) | Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones | |
| SE0000303D0 (sv) | Novel compounds | |
| BRPI0507985A (pt) | derivados de piperazina uréia para o tratamento de endometriose | |
| DE602004022578D1 (de) | Antitumorale terpen-verbindungen | |
| AR062215A1 (es) | Inhibidor de trombina activo por via oral | |
| SE0401716D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |